← All Sana Biotechnology, INC filings

Sana Biotechnology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SANA
Sana Biotechnology, INC
10-K: Sana Biotechnology's 10-K Filing Reveals Progress in Cell Engineering, but Going Concern Uncertainty Remains
Sana Biotechnology's 2024 10-K filing highlights advancements in its cell engineering platforms and clinical trials, particularly in type 1 diabetes, while also acknowledging substantial doubt about its ability to continue as a going concern without additional funding.
NASDAQ
SANA
Sana Biotechnology, INC
10-K: Sana Biotechnology's 10-K Filing Reveals Focus on Hypoimmune Cell Therapies and Manufacturing Expansion
Sana Biotechnology's annual 10-K filing highlights its strategic focus on ex vivo hypoimmune cell therapies, ongoing clinical trials, and investments in manufacturing capabilities.